back to the overview

 

Press Release; Berlin, January 2nd, 2008

 

Founder and long-time Chief Executive Officer, Prof. Burghardt Wittig, joins Strategic Scientific Advisory Council of MOLOGEN AG

 

Berlin, January 2, 2008 – As already notified in the 2007 general shareholders’ meeting, the Berlin based biotech company MOLOGEN AG today announced that the Supervisory Board has appointed Dr. Matthias Schroff from 1st of January 2008 as Chief Executive Officer for three years, as planned. Henceforth the company will be managed by Dr. Matthias Schroff (CEO) and Joerg Petrass (CFO).

 

Dr. Schroff has a degree in biochemistry and has been a member of the Executive Board since 2005, being responsible for operational business matters. He is co-inventor of fundamental patented technologies of MOLOGEN. Already before the incorporation of MOLOGEN AG, Dr. Schroff was the Head Scientist at MOLOGEN GmbH and later became its general manager.

 

“Our product pipeline has an enormous potential, which we will aggressively utilize,” said Dr. Schroff. “Within the upcoming months, the clinical trials for our innovative cancer therapy with dSLIM® will begin. The recent acquisition of a competitor with a comparable development product by a US-pharma giant is impressive proof of the value of our dSLIM technology.”

 

Prof. Dr. Burghardt Wittig, founder and long-time Chief Executive Officer of MOLOGEN AG, will change to the newly founded Strategic Scientific Advisory Council of MOLOGEN, and will thereby remain closely committed to the company. The Council will support the Executive Board in strategic and product development matters.

 

“We would like to thank Prof. Wittig who has successfully steered MOLOGEN AG for many years, and who was one of the first entrepreneurs in the innovative biotech business,” said Dr. Mathias Schlichting, Chairman of the Supervisory Board. “With Dr. Schroff, we have found a capable and experienced successor who will guarantee to continue the success story of MOLOGEN.”

   

About MOLOGEN

MOLOGEN AG, a biopharmaceutical company based in Berlin, specializes in the research and development of innovative medicines based on DNA structures (DNA: deoxyribonucleic acid).

 

Its patented DNA-based technology platforms MIDGE® and dSLIM® form a universal foundation with a wide range of possible applications. Activities focus on product developments for the treatment of cancer and vaccines for serious infections in humans and animals.

 

MOLOGEN was founded in 1998 and was the first German biotechnology company to go public. MOLOGEN AG shares are listed in the General Standard of Deutsche Börse (ISIN DE 0006637200).

 

Disclaimer concerning prognoses

Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this communication regarding planned or future results of business segments, financial classification numbers, developments of the financial situation, or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for these forward-looking statements. It is not responsible for updating such information, which only represents the state of affairs on the day of publication.

 

 back to the overview